CU 106
Alternative Names: CU-106Latest Information Update: 04 Nov 2022
At a glance
- Originator CURACLE
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Angiogenesis modulating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 09 Aug 2022 Preclinical trials in Cancer in South Korea (unspecified route), prior to August 2022 (CURACLE pipeline, August 2022)
- 30 Jun 2022 CURACLE completes a phase I trial in Cancer in USA (PO) (CURACLE pipeline, August 2022)
- 01 Jun 2022 Phase-I clinical trials in Cancer in USA (Injection) (CURACLE pipeline, August 2022)